Xaira Unveils X-Design, De Novo Antibody Design Model

AI drug company Xaira Therapeutics released X-Design, a molecular design model that produced a preclinical lead antibody for an oncology target from DNA in just 7 weeks, showcasing de novo antibody design capabilities.

2026-10-03 ~ 2026-10-05 · 2 related posts

• Xaira's X-Design model designs functional antibodies against an "undruggable" target — DaveJuergens · 2026-10-03
• Xaira Unveils X-Design: Preclinical Lead in 7 Weeks and a Functional Antibody Against a Tough GPCR — BoWang87 · 2026-10-05